Loading…
No. RIR 1–3 produces equivalent hypertrophy with less recovery cost — failure every set raises injury risk.
Modern hypertrophy meta-analyses find RIR 1–3 matches training-to-failure on growth with lower fatigue.
Our read is Not Supported. The claim circulating publicly is not borne out by the evidence — a developing evidence base (74/100) and broad agreement (80% consensus) point the other way. Spending $0/month and medium effort on training to failure on every set is not where we would direct attention; the strongest evidence-based reading is to skip it.
Pulled the public claims about training to failure on every set from the proponents circulating the claim and weighed them against the more cautious voices (a tracked voice), then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Downside risk on training to failure on every set is low at sensible doses, but low risk is not no risk: individual response varies, and a low-risk intervention is still only worth it if the benefit is real.
A rigorous human RCT reversing the current null or harmful signal; absent that, the verdict stands.
The intervention improves the primary outcome at standard doses in healthy adults.
The intervention improves the primary outcome at standard doses in healthy adults.
Benefits hold across the populations where it's been tested.
Mechanistic and trial evidence converge on a real, replicable effect.
Benefits hold across the populations where it's been tested.
Most of the support comes from short or small studies.
The headline effect shrinks once you account for trial quality.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.
The headline effect shrinks once you account for trial quality.